Exact Sciences Corp. (NASDAQ:EXAS)’s share price traded down 1% during mid-day trading on Wednesday . The company traded as low as $12.47 and last traded at $12.60, with a volume of 3,251,396 shares traded. The stock had previously closed at $12.73.

A number of equities analysts have issued reports on the company. William Blair restated an “outperform” rating and set a $29.00 target price on shares of Exact Sciences Corp. in a report on Friday, July 15th. Zacks Investment Research upgraded Exact Sciences Corp. from a “hold” rating to a “buy” rating and set a $8.25 target price on the stock in a report on Tuesday, April 26th. Mizuho cut Exact Sciences Corp. from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $12.00 to $6.50 in a report on Wednesday, May 4th. BTIG Research restated a “buy” rating and set a $9.00 target price on shares of Exact Sciences Corp. in a report on Tuesday, May 24th. Finally, Jefferies Group restated a “buy” rating on shares of Exact Sciences Corp. in a report on Wednesday, May 4th. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $11.52.

The company’s market cap is $1.23 billion. The firm has a 50-day moving average of $10.52 and a 200-day moving average of $7.51.

Exact Sciences Corp. (NASDAQ:EXAS) last issued its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.03. The company earned $14.80 million during the quarter, compared to analyst estimates of $15.17 million. During the same period in the previous year, the company posted ($0.40) EPS. The company’s quarterly revenue was up 244.2% on a year-over-year basis. On average, equities research analysts forecast that Exact Sciences Corp. will post ($2.00) earnings per share for the current fiscal year.

Other large investors recently modified their holdings of the company. California State Teachers Retirement System boosted its stake in shares of Exact Sciences Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 177,702 shares of the company’s stock valued at $1,640,000 after buying an additional 2,809 shares during the last quarter. US Bancorp DE boosted its stake in shares of Exact Sciences Corp. by 2.3% in the fourth quarter. US Bancorp DE now owns 229,594 shares of the company’s stock valued at $2,119,000 after buying an additional 5,109 shares during the last quarter. OppenheimerFunds Inc. boosted its stake in shares of Exact Sciences Corp. by 455.5% in the fourth quarter. OppenheimerFunds Inc. now owns 2,777,430 shares of the company’s stock valued at $25,636,000 after buying an additional 2,277,430 shares during the last quarter. Finally, Eagle Asset Management bought a new stake in shares of Exact Sciences Corp. during the third quarter valued at $39,880,000.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.